Stock listing
Xetra:87E Dianthus Therapeutics, Inc. Aktie
German listing (Xetra) of Dianthus Therapeutics, Inc. · home listing NASDAQ:DNTH
Follow Dianthus Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:DNTH
$84.55 USD +0.57 (+0.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:DNTH
- Day range
- $82.58 – $85.67 USDNov 20, 2026
- Volume
- 784,842 sharesNov 20, 2026
- Market cap
- $4.76B USDAt the close on Nov 20, 2026 · price × 56.31M shares outstanding
- 52-week range
- $35.84 – $117.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $75.93M USDMedian day 735,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DNTH · Home | $84.55 USD | +0.57 (+0.7%) | 784,842 | $83.62 | $85.67 | $82.58 | $83.98 | Close on Nov 20, 2026 |
| Frankfurt:87E | €75.50 EUR | -2.50 (-3.2%) | — | €75.50 | €75.50 | €75.50 | €78.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DNTH · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $84.55 | +0.57 | +0.7% | $83.62 | $85.67 | $82.58 | 784,842 | |
| $83.98 | -3.00 | -3.4% | $86.84 | $89.00 | $83.62 | 841,863 | |
| $86.98 | -2.57 | -2.9% | $89.55 | $90.50 | $85.43 | 553,443 | |
| $89.55 | -2.26 | -2.5% | $90.29 | $93.81 | $87.85 | 558,201 | |
| $91.81 | -0.67 | -0.7% | $91.87 | $92.34 | $88.61 | 681,514 | |
| $92.48 | +3.18 | +3.6% | $88.12 | $92.79 | $83.84 | 921,000 | |
| $89.30 | +0.49 | +0.6% | $89.05 | $90.46 | $87.97 | 735,021 | |
| $88.81 | -1.19 | -1.3% | $89.86 | $90.48 | $86.92 | 511,693 | |
| $90.00 | +3.97 | +4.6% | $87.81 | $91.82 | $84.41 | 700,293 | |
| $86.03 | +3.02 | +3.6% | $84.12 | $87.44 | $82.13 | 593,975 | |
| $83.01 | -2.80 | -3.3% | $85.87 | $85.87 | $80.34 | 1,058,517 | |
| $85.81 | +3.11 | +3.8% | $85.92 | $85.92 | $82.21 | 1,679,408 | |
| $82.70 | +0.45 | +0.5% | $83.21 | $86.17 | $81.91 | 1,525,974 | |
| $82.25 | -0.13 | -0.2% | $83.66 | $84.56 | $80.75 | 837,698 | |
| $82.38 | -0.32 | -0.4% | $81.29 | $83.73 | $80.63 | 496,892 | |
| $82.70 | +0.39 | +0.5% | $82.87 | $84.70 | $81.88 | 849,055 | |
| $82.31 | +2.79 | +3.5% | $77.82 | $82.45 | $77.26 | 656,237 | |
| $79.52 | +0.19 | +0.2% | $79.55 | $81.10 | $78.64 | 748,687 | |
| $79.33 | +2.55 | +3.3% | $77.87 | $79.90 | $77.12 | 501,031 | |
| $76.78 | -1.75 | -2.2% | $76.03 | $78.16 | $76.02 | 379,227 | |
| $78.53 | +0.43 | +0.6% | $77.13 | $78.96 | $75.40 | 1,480,230 | |
| $78.10 | -0.65 | -0.8% | $78.89 | $80.74 | $77.26 | 1,194,116 | |
| $78.75 | +4.21 | +5.6% | $74.61 | $79.93 | $73.17 | 1,865,288 | |
| $74.54 | +2.45 | +3.4% | $73.55 | $76.04 | $72.13 | 972,522 | |
| $72.09 | -2.44 | -3.3% | $74.41 | $75.34 | $69.43 | 1,053,300 | |
| $74.53 | -0.23 | -0.3% | $75.77 | $77.55 | $72.67 | 943,600 | |
| $74.76 | -2.82 | -3.6% | $77.17 | $78.78 | $74.47 | 977,300 | |
| $77.58 | -3.99 | -4.9% | $81.42 | $81.46 | $77.25 | 1,315,400 | |
| $81.57 | -0.80 | -1.0% | $81.77 | $83.77 | $80.91 | 853,900 | |
| $82.37 | -0.06 | -0.1% | $82.36 | $85.20 | $82.13 | 738,900 | |
| $82.43 | -2.45 | -2.9% | $84.73 | $84.85 | $81.06 | 1,003,700 | |
| $84.88 | -0.52 | -0.6% | $84.60 | $86.61 | $84.13 | 562,500 | |
| $85.40 | -2.64 | -3.0% | $88.58 | $88.58 | $83.19 | 1,347,600 | |
| $88.04 | -0.17 | -0.2% | $88.44 | $89.58 | $86.09 | 597,400 | |
| $88.21 | -0.11 | -0.1% | $89.05 | $91.24 | $87.73 | 751,400 | |
| $88.32 | +0.27 | +0.3% | $88.40 | $91.04 | $87.22 | 767,000 | |
| $88.05 | +0.89 | +1.0% | $88.19 | $90.71 | $87.58 | 1,030,800 | |
| $87.16 | -0.67 | -0.8% | $87.40 | $87.69 | $84.72 | 1,033,900 | |
| $87.83 | -0.72 | -0.8% | $88.03 | $89.14 | $87.04 | 652,700 | |
| $88.55 | -2.16 | -2.4% | $91.56 | $92.89 | $88.34 | 522,700 | |
| $90.71 | -2.73 | -2.9% | $93.75 | $94.95 | $90.36 | 726,200 | |
| $93.44 | -4.91 | -5.0% | $98.35 | $98.53 | $89.78 | 1,187,400 | |
| $98.35 | +1.88 | +1.9% | $96.84 | $100.47 | $96.55 | 1,124,800 | |
| $96.47 | -0.34 | -0.4% | $95.95 | $99.67 | $94.58 | 933,200 | |
| $96.81 | -4.31 | -4.3% | $101.12 | $104.55 | $96.47 | 2,829,300 | |
| $101.12 | -1.37 | -1.3% | $104.58 | $105.85 | $99.92 | 1,140,600 | |
| $102.49 | -2.28 | -2.2% | $105.43 | $107.00 | $101.60 | 1,035,500 | |
| $104.77 | -2.92 | -2.7% | $107.85 | $108.26 | $104.04 | 479,000 | |
| $107.69 | +1.49 | +1.4% | $108.36 | $109.76 | $106.55 | 651,500 | |
| $106.20 | +2.92 | +2.8% | $106.78 | $109.79 | $105.00 | 732,800 | |
| $103.28 | -3.76 | -3.5% | $105.88 | $107.64 | $101.60 | 535,800 | |
| $107.04 | -2.09 | -1.9% | $108.03 | $110.24 | $105.95 | 1,033,900 | |
| $109.13 | +1.03 | +1.0% | $105.61 | $111.11 | $104.95 | 631,100 | |
| $108.10 | +0.25 | +0.2% | $107.06 | $109.61 | $105.65 | 638,500 | |
| $107.85 | +1.61 | +1.5% | $106.44 | $109.23 | $105.57 | 355,700 | |
| $106.24 | -0.38 | -0.4% | $107.69 | $110.44 | $103.13 | 565,400 | |
| $106.62 | +1.01 | +1.0% | $105.34 | $107.52 | $103.80 | 576,600 | |
| $105.61 | -0.23 | -0.2% | $105.33 | $107.20 | $102.38 | 459,400 | |
| $105.84 | -5.70 | -5.1% | $111.31 | $111.31 | $105.60 | 376,200 | |
| $111.54 | +0.78 | +0.7% | $111.28 | $112.13 | $109.69 | 601,200 | |
| $110.76 | -1.35 | -1.2% | $111.44 | $111.56 | $109.54 | 335,400 | |
| $112.11 | +2.04 | +1.9% | $112.23 | $113.86 | $110.20 | 552,000 | |
| $110.07 | -1.03 | -0.9% | $110.08 | $111.81 | $105.05 | 531,900 | |
| $111.10 | +1.59 | +1.5% | $110.30 | $112.72 | $108.95 | 730,900 | |
| $109.51 | -4.19 | -3.7% | $111.73 | $112.82 | $107.36 | 735,500 |
Splits
1 split · NASDAQ:DNTH · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation |
- Ticker
- Xetra:87E
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Xetra
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 97 slides
Latest news
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Nov 4, 2026
Closed $83.01 (-3.3%) on Nov 5, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 2, 2026
Closed $82.70 (+0.5%) on Nov 3, 2026
Dianthus Therapeutics to Participate in Five Investor Conferences During November
Nov 2, 2026
Closed $82.70 (+0.5%) on Nov 3, 2026
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Oct 13, 2026
Closed $77.58 (-4.9%) on Oct 13, 2026
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Sep 29, 2026
Closed $87.16 (-0.8%) on Sep 29, 2026
Dianthus Therapeutics to Participate in Three Investor Conferences During September
Sep 1, 2026
Closed $106.62 (+1.0%) on Sep 1, 2026
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
Aug 4, 2026
Closed $112.50 (+1.9%) on Aug 5, 2026
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Jun 29, 2026
Closed $95.68 (+0.3%) on Jun 29, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
Jun 3, 2026
Closed $84.97 (+4.2%) on Jun 3, 2026
Dianthus Therapeutics to Participate in Two Investor Conferences
May 26, 2026
Closed $86.67 (-0.2%) on May 27, 2026
Dianthus Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 132 in all · newest Nov 4, 2026 · oldest 2019
- Decks
- 18 decks · latest August 2026
Where Dianthus Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DNTH · Home listing | NASDAQ | United States | USD |
| gettex:87E | gettex | Germany | EUR |
| Tradegate:87E | Tradegate | Germany | EUR |
| LS Exchange:A3ERZ4 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3ERZ4 | Lang & Schwarz | Germany | EUR |
| BOATS:DNTH | BOATS | United States | USD |
| Dusseldorf:87E | Dusseldorf | Germany | EUR |
| Frankfurt:87E | Frankfurt | Germany | EUR |
| Munich:87E | Munich | Germany | EUR |
| Stuttgart:87E | Stuttgart | Germany | EUR |
| Xetra:87E · This page | Xetra | Germany | EUR |
Valuation
EV/sales 1,444× against a median of 5.7×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.92B USD
- P/E
- Loss
- EV/sales
- 1,444×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.8×
- Gross margin
- 97.2%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.90
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.08B | US$4.80B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Median of the others | US$4.75B | US$4.23B | 29.2× | 5.7× | 25.0× | 6.6× | −12.2% | 0.0× | 1.13 |
Forecasts
17 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 139.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.56 · 10 analysts
- Revenue, year to Dec 2026
- 2.6M · 14 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Marino Garcia | President & Chief Executive Officer, Board Member |
| Ryan Savitz | Executive Vice President, Chief Financial Officer & Chief Business Officer |
| Adam Veness | General Counsel |
| Jennifer Davis Ruff | Head of Investor Relations and Corporate Affairs |
| Jennifer Cross | VP, Pipeline Strategy & Research |
| Simrat Randhawa | Executive Vice President, Head of R&D |
| Edward Carr | Chief Accounting Officer |
| Judson Taylor | Head of Technical Operations |
| Kristina Maximenko | Chief People Officer |
| Polly Hanff | Head of Quality |
| Rivka Gluck | Head of Clinical Development Operations |
| Ronny Hashmonay | Chief Development and Medical Affairs Officer |
| Scott Nogi | Head of Business Operations |
| Sue Evans | Head of Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Marino Garcia | President & Chief Executive Officer, Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −3.3% |
| Q2 2026 | Aug 4, 2026 · After close | +1.9% |
| Q1 2026 | May 5, 2026 · After close | +0.2% |
| Q4 2025 | Mar 9, 2026 | +33.3% |
| Q3 2025 | Nov 5, 2025 · After close | +8.0% |
| Q2 2025 | Aug 7, 2025 · After close | −2.0% |
| Q1 2025 | May 12, 2025 · After close | −6.2% |
| Q4 2024 | Mar 19, 2025 · Before open | −0.7% |
| Q3 2024 | Nov 7, 2024 · After close | −2.8% |
| Q2 2024 | Aug 8, 2024 · After close | +2.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −2.6% |
| Q4 2023 | Mar 21, 2024 · After close | +14.3% |
| Q3 2023 | Nov 9, 2023 · After close | +0.8% |
| Q2 2023 | Sep 18, 2023 | +1.1% |
| Q1 2023 | May 11, 2023 | −10.7% |
| Q4 2022 | Mar 7, 2023 | −1.9% |
| Q3 2022 | Nov 3, 2022 | −2.4% |
| Q2 2022 | Aug 4, 2022 | +14.7% |
| Q1 2022 | May 16, 2022 | +3.5% |
| Q4 2021 | Mar 8, 2022 | +14.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 97 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 94 slides | Jun 12, 2026 |
| Investor Presentation (March 2026) | Investor deck | 84 slides | Mar 26, 2026 |
| Corporate Update (March 2026) | Corporate update | 22 slides | Mar 9, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 29 slides | Jan 12, 2026 |
| Investor Presentation (January 2026) | Investor deck | 74 slides | Jan 12, 2026 |
| Investor Presentation (November 2025) | Investor deck | 72 slides | Nov 3, 2025 |
| Merger or Acquisition (October 2025) | Merger or acquisition | 19 slides | Oct 16, 2025 |
| Investor Presentation (September 2025) | Investor deck | 32 slides | Sep 8, 2025 |
| Virtual Industry Forum (2025) | Conference | 27 slides | 2025 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2024) | Investor deck | 31 slides | Dec 12, 2024 |
| Investor Presentation (June 2024) | Investor deck | 27 slides | Jun 6, 2024 |
| Investor Presentation (January 2024) | Investor deck | 25 slides | Jan 8, 2024 |
| Magenta Therapeutics — Merger or Acquisition (August 2023) | Merger or acquisition | 22 slides | Aug 31, 2023 |
| Magenta Therapeutics — Merger or Acquisition (May 2023) | Merger or acquisition | 28 slides | May 3, 2023 |
| Magenta Therapeutics — ASH Annual Meeting 2022 | Conference | 31 slides | Dec 13, 2022 |
| Magenta Therapeutics — Investor Presentation (January 2020) | Investor deck | 43 slides | Jan 13, 2020 |
| Magenta Therapeutics — Investor Presentation (January 2019) | Investor deck | 40 slides | Jan 7, 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Closed: US$288M raised · US$33 a share · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Stifel (co-lead), LifeSci Capital Use of proceeds: Advance preclinical and clinical development activities, working capital and general corporate purposes | Sep 11, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Magenta Therapeutics, Inc. Priced at US$15.00 a share on Jun 20, 2018.
- Price
- US$15.00 a share
- Shares offered
- 6,666,667 shares of common stock
- Offering size
- US$100 million
- Underwriters' option
- Up to 1,000,000 more shares
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Wedbush PacGrow · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 28, 2018 |
| Filed publicly | May 24, 2018 |
| Amended 3 times | Newest Jun 19, 2018 |
| Shares registered with an exchange | Jun 19, 2018 |
| Declared effective by the SEC | Jun 20, 2018 |
| Final prospectus, with the price | Jun 21, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 21, 2018 |
| EFFECT · Notice that a registration is effective | Jun 20, 2018 |
| CERT · Exchange's certificate of listing | Jun 20, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 19, 2018 |
| FWP · Free writing prospectus | Jun 19, 2018 |
| S-1/A · Registration statement, amended | Jun 19, 2018 |
| CORRESP · Letter to the SEC | Jun 18, 2018 |
| CORRESP · Letter to the SEC | Jun 18, 2018 |
| S-1/A · Registration statement, amended | Jun 18, 2018 |
| UPLOAD · Letter from the SEC | Jun 8, 2018 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 8, 2018 |
| S-1/A · Registration statement, amended | Jun 8, 2018 |
| CORRESP · Letter to the SEC | May 31, 2018 |
| CORRESP · Letter to the SEC | May 24, 2018 |
| S-1 · Registration statement | May 24, 2018 |
| UPLOAD · Letter from the SEC | May 16, 2018 |
| DRS/A · Draft registration statement, amended | May 8, 2018 |
| DRSLTR · Letter to the SEC with a draft | May 7, 2018 |
| UPLOAD · Letter from the SEC | Apr 24, 2018 |
| DRS · Draft registration statement | Mar 28, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 21, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | 0 | 0 | 0 | 0 | |
| Cost of revenue | 412.0K | 355.0K | 147.0K | 2.02M | 1.98M | 1.84M | 875.0K | 376.0K | 6.00K | |
| Gross profit | 2.04M | 6.24M | 2.83M | 6.42M | 1.48M | -1.98M | -1.84M | -875.0K | -376.0K | -6.00K |
| Research and development | 145.6M | 83.1M | 32.8M | 29.4M | 46.8M | 50.6M | 59.2M | 41.3M | 27.9M | 5.78M |
| Selling, general and administrative | 34.3M | 25.0M | 18.2M | 6.74M | 1.96M | 28.1M | 23.8M | 18.6M | 7.83M | 3.49M |
| Operating income | -177.9M | -101.9M | -48.2M | -29.7M | -74.7M | -78.7M | -83.0M | -60.0M | -35.7M | -9.27M |
| Depreciation and amortization | 111.0K | 96.0K | 67.0K | 1.93M | 2.02M | 1.98M | 1.84M | 875.0K | 376.0K | 6.00K |
| EBITDA | -177.8M | -101.8M | -48.1M | -27.8M | -72.7M | -76.7M | -81.1M | -59.1M | -35.4M | -9.26M |
| Interest expense | 3.56M | 3.77M | 163.0K | |||||||
| Income before tax | -162.3M | -85.0M | -43.6M | -28.5M | -13.1M | -74.9M | -76.8M | -57.5M | -35.5M | -9.43M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -162.3M | -85.0M | -43.6M | -28.5M | -71.1M | -74.9M | -76.8M | -57.5M | -35.5M | -9.43M |
| Earnings per share, basic | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 | -1.71 | -2.07 | -3.13 | -19.12 | -65.15 |
| Earnings per share, diluted | -4.20 | -2.55 | -8.45 | -32.57 | -1.29 | -1.71 | -2.07 | -3.13 | -19.12 | -65.15 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 51.1M | 22.8M | 132.3M | 15.4M | 131.7M | 58.2M | 65.1M | 58.3M | 51.4M | 4.51M |
| Short-term investments | 353.2M | 252.4M | 41.4M | 60.1M | 45.3M | 90.7M | 80.7M | 84.2M | ||
| Receivables | 52.0K | 0 | 294.0K | 4.70M | 1.48M | 6.25M | ||||
| Inventory | 852.0K | 264.0K | ||||||||
| Current assets | 409.4M | 280.9M | 177.5M | 82.0M | 180.7M | 151.5M | 149.8M | 145.3M | 52.5M | 10.8M |
| Property, plant and equipment | 296.0K | 194.0K | 185.0K | 142.0K | 7.46M | 8.31M | 9.89M | 10.2M | 1.96M | |
| Total assets | 530.9M | 374.0M | 179.4M | 83.1M | 189.9M | 161.6M | 161.5M | 157.3M | 54.5M | 11.3M |
| Accounts payable | 9.72M | 4.58M | 2.61M | 1.17M | 3.04M | 3.76M | 2.81M | 3.49M | 167.0K | 1.67M |
| Current liabilities | 30.7M | 18.5M | 9.63M | 8.22M | 10.9M | 11.4M | 14.1M | 10.4M | 4.14M | 2.30M |
| Total debt | 1.39M | 1.49M | 585.0K | 788.0K | ||||||
| Total liabilities | 37.5M | 21.5M | 10.5M | 9.45M | 17.3M | 17.7M | 20.3M | 11.7M | 4.14M | 2.30M |
| Shareholders' equity | 493.4M | 352.5M | 168.9M | -44.4M | -17.2M | 143.9M | 141.2M | 145.6M | -42.1M | -8.87M |
| Shares outstanding | 43.2M | 31.1M | 14.8M | 875.3K | 58.8M | 48.5M | 39.3M | 33.3M | 2.35M | 39.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -129.1M | -78.2M | -36.9M | -29.1M | -59.5M | -64.0M | -57.1M | -41.9M | -22.3M | -6.53M |
| Capital spending | -213.0K | -105.0K | -110.0K | -314.0K | -1.26M | -400.0K | -3.06M | -7.67M | -2.20M | -139.0K |
| Free cash flow | -129.3M | -78.3M | -37.0M | -29.4M | -60.8M | -64.4M | -60.2M | -49.6M | -24.5M | -6.67M |
| Cash from investing | -122.8M | -286.8M | 20.3M | -59.8M | 43.4M | -10.6M | 1.53M | -91.7M | -2.20M | -139.0K |
| Cash from financing | 280.1M | 255.6M | 133.6M | 96.7M | 89.6M | 67.7M | 62.3M | 142.1M | 71.5M | 10.7M |
| Share buybacks | 317.0K | -88.0K | -213.0K | -107.0K | ||||||
| Change in cash | 28.2M | -109.4M | 117.0M | 7.79M | 73.5M | -6.92M | 6.73M | 8.56M | 47.0M | 4.04M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Sep 18, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Sep 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 8-K · Current report | May 22, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 9, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 9, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 9, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Mar 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 11, 2026 | Offer document | SEC |
| S-3MEF | Mar 10, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 9, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 29, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 28, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 19, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 8-K · Current report | Oct 16, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 424B5 · Prospectus | Sep 8, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 8, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2025 | Insider trade | SEC |
| 8-K · Current report | May 22, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 17, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 10, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 10, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 19, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 11, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 5, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 3, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 22, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| RW · Request to withdraw a registration | Oct 21, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 11, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Oct 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 7, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 7, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| S-3 · Registration statement | Oct 1, 2024 | Offer document | SEC |
| S-3 · Registration statement | Oct 1, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Sep 16, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 12, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 8, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jun 6, 2024 | Current report | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
This page holds 200 of 661 filings. Open Filings
Cap table
Built by 6ix from Dianthus Therapeutics, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 56,312,712
- Fully diluted
- 56,312,712
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 56,312,712 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 56,312,712 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bruce Booth Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Tectonic Therapeutic, Inc. (Director · Jun 10, 2021 – Jun 6, 2023 · Past) | Director · Jun 1, 2021 – Jun 28, 2022 · Past |
| Leon O Moulder Jr Other companies: Zenas BioPharma, Inc. (See Remarks, Director · Since at least Sep 12, 2024); Zai Lab Ltd. (Director · Since at least Jan 1, 2021); Trevena, Inc. (Director · May 16, 2018 – Jun 15, 2023 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past) | Director · Sep 11, 2023 – May 23, 2024 · Past |
| Jeffrey Humphrey Other companies: Lantheus Holdings, Inc. (Chief Medical Officer · May 28, 2024 – Jun 17, 2024 · Past); Cyteir Therapeutics Inc (Director · Dec 15, 2021 – Feb 3, 2023 · Past); Constellation Pharmaceuticals Inc (Chief Medical Officer · Jun 22, 2020 – Jul 15, 2021 · Past) | Chief Medical Officer · Oct 1, 2021 – Aug 1, 2022 · Past |
| Adam Veness Other companies: Cyteir Therapeutics Inc (General Counsel · Apr 25, 2022 – Feb 3, 2023 · Past); Acceleron Pharma Inc (SVP, General Counsel and Sec. · Jan 4, 2021 – Nov 19, 2021 · Past) | General Counsel · Since at least Sep 11, 2023 |
| Marino Garcia Other companies: AgomAb Therapeutics NV (Director · Since at least Sep 11, 2026); Synergy Pharmaceuticals Inc (EVP and Chief Strategy Officer · Jan 5, 2018 – Jan 5, 2018 · Past) | President & Chief Executive Officer, Board Member · Since at least Sep 11, 2023 |
| Steven J Romano Other companies: Silence Therapeutics PLC (EVP and Chief R&D Officer · Since at least Jan 2, 2025); Mallinckrodt Inc (EVP & Chief Sci. Ofcr · Jun 16, 2022 – Jun 16, 2022 · Past) | Director · Since at least Sep 16, 2024 |
| Sujay Kango Other companies: Lite Strategy, Inc. (Director · Nov 22, 2021 – Sep 29, 2023 · Past); Acceleron Pharma Inc (EVP, Chief Commercial Officer · Feb 12, 2018 – Nov 19, 2021 · Past) | Director · Since at least Mar 4, 2025 |
| Amy Ronneberg Other companies: Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024) | Director · Jun 20, 2018 – Jun 28, 2022 · Past |
| Cindy Driscoll Other companies: Climb Bio, Inc. (Senior Vice President, Finance · Since at least Jun 17, 2025) | See Remarks · Jun 20, 2018 – Oct 1, 2020 · Past |
| Edward Carr Other companies: Abeona Therapeutics Inc. (Chief Financial Officer · Nov 9, 2018 – Oct 8, 2021 · Past) | Chief Accounting Officer · Since at least Sep 11, 2023 |
All 19 people
| Person | Seat |
|---|---|
| Paula Soteropoulos Other companies: Rallybio Corporation (Lead Independent Director · Since at least May 13, 2025) | Director · Since at least May 22, 2025 |
| David Wayne Nichols | Chief Technical Officer · May 17, 2022 – Aug 1, 2022 · Past |
| Jason Gardner | See Remarks, Director · Jun 20, 2018 – Nov 30, 2022 · Past |
| Jennifer Davis Ruff | Head of Investor Relations and Corporate Affairs · Since at least Nov 4, 2026 |
| Lisa Olson | See Remarks · Sep 14, 2020 – Aug 1, 2022 · Past |
| Michael David Gregory | Director · Jan 22, 2024 – Jan 22, 2024 · Past |
| Ryan Savitz | Executive Vice President, Chief Financial Officer & Chief Business Officer · Since at least Mar 31, 2026 |
| Simon Read | Director · Since at least May 22, 2025 |
| Simrat Randhawa | Executive Vice President, Head of R&D · Since at least Sep 11, 2023 |
Log in to ask 6ix AI your own questions about Dianthus Therapeutics, Inc.